RedHill Biopharma Ltd. – NASDAQ:RDHL
Founder-led company
RedHill Biopharma Ltd. stock price today
$1.42
-5.49
-79.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
RedHill Biopharma Ltd. stock price monthly change
+1676.35%
month
RedHill Biopharma Ltd. stock price quarterly change
+1676.35%
quarter
RedHill Biopharma Ltd. stock price yearly change
+400.73%
year
RedHill Biopharma Ltd. key metrics
Market Cap | 8.10M |
Enterprise value | 105.73M |
P/E | -0.05 |
EV/Sales | 1.38 |
EV/EBITDA | -3.76 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -18.58 |
Revenue | 35.74M |
EBITDA | 111.71M |
Income | -10.80M |
Revenue Q/Q | -90.21% |
Revenue Y/Y | -55.46% |
Profit margin | -116.69% |
Oper. margin | -65.88% |
Gross margin | 39.88% |
EBIT margin | -65.88% |
EBITDA margin | 312.53% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRedHill Biopharma Ltd. stock price history
RedHill Biopharma Ltd. stock forecast
RedHill Biopharma Ltd. financial statements
| Sep 2022 | 17.55M | -64.29M | -366.31% |
|---|---|---|---|
| Dec 2022 | 12.79M | 2.49M | 19.46% |
| Mar 2023 | 3.59M | 50.24M | 1395.97% |
| Jun 2023 | 1.79M | 761K | 42.37% |
| 2025 | 38M | -2.59M | -6.82% |
|---|---|---|---|
| 2026 | 50.6M | 0 |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 157192000 | 203.21M | 129.28% |
|---|---|---|---|
| Dec 2022 | 158870000 | 207.27M | 130.47% |
| Mar 2023 | 58834000 | 56.83M | 96.59% |
| Jun 2023 | 35037000 | 31.56M | 90.09% |
| Sep 2022 | -6.02M | -22K | -5.72M |
|---|---|---|---|
| Dec 2022 | -2.42M | -8.5M | 7.20M |
| Mar 2023 | -7.18M | 0 | 4.81M |
| Jun 2023 | -10.58M | -7K | 3K |
RedHill Biopharma Ltd. alternative data
| Aug 2023 | 113 |
|---|---|
| Sep 2023 | 113 |
| Oct 2023 | 113 |
| Nov 2023 | 113 |
| Dec 2023 | 113 |
| Jan 2024 | 113 |
| Feb 2024 | 113 |
| Mar 2024 | 113 |
| Apr 2024 | 113 |
| May 2024 | 53 |
| Jun 2024 | 53 |
| Jul 2024 | 53 |
RedHill Biopharma Ltd. other data
0.49%
-4.09%
of RDHL is owned by hedge funds
13
-26
28.23K
-236.25K
shares is hold by hedge funds
| Patent |
|---|
Grant Filling date: 15 Oct 2021 Issue date: 21 Jun 2022 |
Application SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION IN MODERATELY SEVERE PATIENTS WITH PNEUMONIA Filling date: 15 Dec 2021 Issue date: 16 Jun 2022 |
Application Filling date: 20 Aug 2021 Issue date: 3 Mar 2022 |
Application Filling date: 15 Oct 2021 Issue date: 3 Feb 2022 |
Application TRIPLE ANTIBIOTIC FIXED-DOSE COMBINATION PRODUCTS, DOSING REGIMEN, METHODS, AND KITS FOR TREATING PULMONARY NON-TUBERCULOSIS MYCOBACTERIAL INFECTIONS Filling date: 30 Jun 2021 Issue date: 30 Dec 2021 |
Application Filling date: 13 Aug 2021 Issue date: 2 Dec 2021 |
Application Filling date: 7 May 2020 Issue date: 11 Nov 2021 |
Application Filling date: 30 Jun 2021 Issue date: 21 Oct 2021 |
Grant Filling date: 18 Jul 2019 Issue date: 5 Oct 2021 |
Application Filling date: 10 Jun 2021 Issue date: 30 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2022 23 Jun 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 17 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 30 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 26 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Rick D. Scruggs (1960) Chief Commercial Officer, Head of US Operations & Director | $577,990 |
Mr. Dror Ben-Asher (1966) Co-Founder, Chairman & Chief Executive Officer | $555,970 |
Mr. Micha Ben-Chorin (1969) Chief Financial Officer | $418,050 |
Mr. Adi Frish (1970) Chief Corporation & Bus. Devel. Officer | $407,210 |
Mr. Gilead Raday (1975) Chief Operating Officer | $388,250 |
-
What's the price of RedHill Biopharma Ltd. stock today?
One share of RedHill Biopharma Ltd. stock can currently be purchased for approximately $1.42.
-
When is RedHill Biopharma Ltd.'s next earnings date?
Unfortunately, RedHill Biopharma Ltd.'s (RDHL) next earnings date is currently unknown.
-
Does RedHill Biopharma Ltd. pay dividends?
No, RedHill Biopharma Ltd. does not pay dividends.
-
How much money does RedHill Biopharma Ltd. make?
RedHill Biopharma Ltd. has a market capitalization of 8.10M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 89.46% to 6.51M US dollars.
-
What is RedHill Biopharma Ltd.'s stock symbol?
RedHill Biopharma Ltd. is traded on the NASDAQ under the ticker symbol "RDHL".
-
What is RedHill Biopharma Ltd.'s primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of RedHill Biopharma Ltd.?
Shares of RedHill Biopharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are RedHill Biopharma Ltd.'s key executives?
RedHill Biopharma Ltd.'s management team includes the following people:
- Mr. Rick D. Scruggs Chief Commercial Officer, Head of US Operations & Director(age: 65, pay: $577,990)
- Mr. Dror Ben-Asher Co-Founder, Chairman & Chief Executive Officer(age: 59, pay: $555,970)
- Mr. Micha Ben-Chorin Chief Financial Officer(age: 56, pay: $418,050)
- Mr. Adi Frish Chief Corporation & Bus. Devel. Officer(age: 55, pay: $407,210)
- Mr. Gilead Raday Chief Operating Officer(age: 50, pay: $388,250)
-
Is RedHill Biopharma Ltd. founder-led company?
Yes, RedHill Biopharma Ltd. is a company led by its founder Mr. Dror Ben-Asher.
-
How many employees does RedHill Biopharma Ltd. have?
As Jul 2024, RedHill Biopharma Ltd. employs 53 workers, which is 53% less then previous quarter.
-
When RedHill Biopharma Ltd. went public?
RedHill Biopharma Ltd. is publicly traded company for more then 12 years since IPO on 7 Jan 2013.
-
What is RedHill Biopharma Ltd.'s official website?
The official website for RedHill Biopharma Ltd. is redhillbio.com.
-
How can i contact RedHill Biopharma Ltd.?
RedHill Biopharma Ltd. can be reached via phone at +972 3 541 3131.
RedHill Biopharma Ltd. company profile:
RedHill Biopharma Ltd.
redhillbio.comExchange:
NASDAQ
Full time employees:
53
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
21 Ha’arba’a Street
Tel Aviv, 6473921
Tel Aviv, 6473921
CIK: 0001553846
ISIN: US7574682024
CUSIP: 757468103
